Skip to content



Open Access

HIV-associated multicentric castelman disease, a report of 5 cases

  • Sylvie Jonckheere1Email author,
  • Jean-Cyr Yombi1,
  • Anne Vincent1,
  • Leila Belkhir1,
  • Dunja Wilmes1 and
  • Bernard Vandercam1
Retrovirology20129(Suppl 1):P136

Published: 25 May 2012


Treatment RegimenChemotherapy RegimenLaboratory FindingImaging ResultFuture Treatment


Multicentric Castleman’s disease (MCD) is a rare, non-clonal lymphoproliferative disorder characterized by constitutional symptoms, anaemia and generalised lymphadenopathy.


The present study intends to compare demographic features, clinical presentation, laboratory studies, imaging results as well as treatment regimens and out- come in our MCD patients to those of larger reported series.


We reviewed the files of 930 HIV-1-infected patients from our AIDS Reference Centre. Data was collected from the operating software for the patients’ medical records of our institution.


We report a series of five cases of MCD among our HIV/AIDS patients’ cohort. Three were of African origin. They were diagnosed after 2003, after a mean duration of 85 months of HIV-seropositivity. All presented with characteristic clinical features and laboratory findings (table 1), and all but one patient were started on HAART only a few months before or upon MCD diagnosis. Four patients were treated with chemotherapy, and one with HAART only. One patient who was given Adriamycin/Bleomycin/Vinblastin is in continuous remission after 6 years of follow-up. Two are alive, with good symptom control, regardless of the treatment they received. One recently relapsed, and one unfortunately died before completing the intended 6-courses chemotherapy regimen.


MCD is a rare, but rising issue among HIV-infected patients. The clinical and paraclinical features of our series of five patients are in keeping with those of larger reported series. Currently, treatment is mainly chemotherapy-based, but a wide variety of protocols have been used, mainly because of the lack of available evidence. New approaches such as anti-CD 20 antibodies seem highly effective, and the role of HHV-8 needs to be further investigated, as it might be an important target for future treatment.

Authors’ Affiliations

Medecine Interne Infectiologie at Centre Refrence St Luc Ucl, Bruxelles, Belgium


© Yombi et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.